Genetic mutations

New data from the phase 1 CHRYSALIS study, which has evaluated Amivantamab in patients with metastatic or unresectable non-small cell...


The U.S. Food and Drug Administration ( FDA ) has approved Lumakras ( Sotorasib ) as the first treatment for...


The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake...


Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...


The FDA ( U.S. Food and Drug Administration ) has approved Tagrisso ( Osimertinib ) as the first adjuvant treatment...


The FDA ( U.S. Food and Drug Administration ) has approved Onureg ( Azacitidine 300 mg tablets, CC-486 ) for...


The FDA ( Food and Drug Administration ) has approved Gavreto ( Pralsetinib ) for the treatment of adults with...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Balversa ( Erdafitinib ), a treatment...


The U.S. Food and Drug Administration ( FDA ) has approved Zolgensma ( Onasemnogene abeparvovec-xioi ), the first gene therapy...


The European Commission ( EC ) has approved Lynparza ( Olaparib ) as a 1st-line maintenance treatment for women with...


Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy ( BKI ) released a...


Acute myeloid leukemia ( AML ) remains a highly resistant disease to conventional chemotherapy, with a median survival of only...


The FDA ( U.S. Food and Drug Administration ) has approved Tibsovo ( Ivosidenib ) tablets for the treatment of...


Results of the global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met...



Researchers at Columbia University Medical Center ( CUMC ) have discovered that the fusion of two adjacent genes can...


The objective of a study was to investigate the kinetics and metabolism of Caffeine in serum from patients with Parkinson...


Shorter sleep duration was associated with increased risk of death from prostate cancer in men under the age of 65. There...


Results from two phase 3 studies of the Tezacaftor ( VX-661 ) / Ivacaftor combination treatment that showed statistically significant...


Muscle biopsy results from 4053-101 study, a phase 1/2 first-in-human study conducted in Europe to assess the safety, tolerability, pharmacokinetics,...